Evolution of the candidacy requirements and patient perioperative assessment protocols for cochlear implantationa

• Published in: The Journal of the Acoustical Society of America Vol. 152; no. 6; pp. 3346 - 3359
• Main Authors: Biever, Allison, Kelsall, David C, Lupo, J Eric, Haase, Gerald M
• Format: Journal Article
• Language: English
• Published: 01-12-2022
• ISSN: 0001-4966; 1520-8524
• DOI: 10.1121/10.0016446

Cochlear implantation as an approved clinical therapy ushered in an exciting era of innovation for the treatment of hearing loss. The U.S. Food and Drug Administration approved the use of cochlear implants as a treatment option for adults with profound sensorineural hearing loss in 1985. The landscape for treating adults and children with significant hearing loss has changed dramatically over the last three decades. The purpose of this paper is to examine the evolving regulatory process and changes to clinical care. A significant emerging trend in cochlear implantation is the consideration of steroids to preserve hearing during and following surgery. This parallels the quest for hearing preservation in noise-induced hearing disorders, especially considering the current interest in biological drug therapies in this population. The future will likely usher in an era of combination therapeutics utilizing drugs and cochlear implantation. For over 30+ years and following regulatory compliance, the Rocky Mountain Ear Center has developed an extensive candidacy and outcome assessment protocol. This systematic approach evaluates both unaided and aided auditory performance during candidacy stages and post-implantation. Adjunctive measures of cognition and quality-of-life augment the auditory assessment in specific populations. Practical insights into lessons learned have directed further clinical research and have resulted in beneficial changes to clinical care.